Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Healthstream (HSTM) Research & Development (2016 - 2026)

Healthstream has reported Research & Development over the past 16 years, most recently at $14.8 million for Q4 2025.

  • Quarterly Research & Development rose 16.35% to $14.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $51.0 million through Dec 2025, up 4.28% year-over-year, with the annual reading at $51.0 million for FY2025, 4.28% up from the prior year.
  • Research & Development was $14.8 million for Q4 2025 at Healthstream, up from $12.1 million in the prior quarter.
  • Over five years, Research & Development peaked at $14.8 million in Q4 2025 and troughed at $9.5 million in Q1 2021.
  • The 5-year median for Research & Development is $11.7 million (2022), against an average of $11.6 million.
  • Year-over-year, Research & Development surged 32.01% in 2021 and then fell 5.01% in 2023.
  • A 5-year view of Research & Development shows it stood at $11.5 million in 2021, then grew by 3.08% to $11.8 million in 2022, then rose by 1.04% to $11.9 million in 2023, then grew by 6.3% to $12.7 million in 2024, then increased by 16.35% to $14.8 million in 2025.
  • Per Business Quant, the three most recent readings for HSTM's Research & Development are $14.8 million (Q4 2025), $12.1 million (Q3 2025), and $12.1 million (Q2 2025).